We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Biogen Inc | NASDAQ:BIIB | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 2.76 | 1.28% | 217.58 | 215.00 | 218.65 | 218.66 | 214.70 | 215.56 | 916,376 | 23:45:38 |
From May 2022 to May 2024
By Sabela Ojea
Biogen Inc. said Thursday that the European Medicines Agency committee has accepted a marketing authorization application for its Alzheimer's drug.
Earlier this month, the Food and Drug Administration gave early approval to the treatment, Lecanemab.
The drug should be delivered to patients diagnosed with a mild cognitive impairment or a mild dementia stage of disease, Biogen said.
The biotechnology company developed the treatment with Tokyo-based Eisai Co., Ltd.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
January 26, 2023 19:11 ET (00:11 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Biogen Chart |
1 Month Biogen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
